Mark T. Sullivan

2.6k citations

54 papers · 1.9k · h-index 16

Impact in

Hepatology top 2%
- Hepatitis C virus research
Epidemiology top 5%
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment

Papers in

Virology 6
- HIV Research and Treatment 6
Infectious Diseases 10
- HIV/AIDS drug development and treatment 6

Co-authors: Carol L. Brosgart (7 shared papers)Ramin Ebrahimi (3 shared papers)Kristin Kleber (3 shared papers)Paul B. Martin (3 shared papers)Marion G. Peters (2 shared papers)Peter Buggisch (2 shared papers)Shengfeng Xiong (2 shared papers)CHRISTIAN G. TREPO (1 shared paper)
Journals: Journal of Hepatology (5 papers)Gastroenterology (4 papers)PLoS neglected tropical diseases (3 papers)American Journal of Health-System Pharmacy (3 papers)Advances in Space Research (2 papers)
Partner nations: United States Australia United Kingdom

In The Last Decade

Mark T. Sullivan

50 papers receiving 1.8k citations

Peers

Countries citing papers authored by Mark T. Sullivan

Since Specialization

Citations

This map shows the geographic impact of Mark T. Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Sullivan more than expected).

Fields of papers citing papers by Mark T. Sullivan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Sullivan. The network helps show where Mark T. Sullivan may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark T. Sullivan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark T. Sullivan Line = papers co-authored together Mark T. Sullivan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Gastroenterology ·Marion G. Peters, Hie‐Won Hann, Paul B. Martin, E. Jenny Heathcote, Peter Buggisch, Rainbow Rubin, Marc Bourliere, Kris V. Kowdley	2003	467
2	The Lunar Reconnaissance Orbiter Diviner Lunar Radiometer Experiment Space Science Reviews ·David A. Paige, M. C. Foote, Benjamin Greenhagen, John T. Schofield, S. B. Calcutt, Ashwin R. Vasavada, Daniel J. Preston, F. W. Taylor	2009	346
3	A framework for the development of effective anti-metastatic agents Nature Reviews Clinical Oncology ·Robin L. Anderson, Theo Balasas, Juliana Callaghan, Raoul Charles Coombes, JEFF EVANS, Jacqueline A. Hall, Sally A. Kinrade, David Jones	2018	273
4	Lamivudine therapy for chronic hepatitis B: A six-month randomized dose- ranging study Gastroenterology ·Frederik Nevens, Janice Main, Pieter Honkoop, DL Tyrrell, Judy Barber, Mark T. Sullivan, Johan Fevery, RA De Man	1997	252
5	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers Science Translational Medicine ·C. Glenn Begley, Mark R. Ashton, Jonathan B. Baell, Michael D. Bettess, Michael P. Brown, Brett Anthony Carter, William N. Charman, Christopher Davis	2021	108
6	BaBar technical design report High-Energy Physics Literature Database (CERN, DESY, Fermilab, IHEP, and SLAC) ·D. Boutigny, Steven J. Yellin, J. Lidbury, V. Dodonov, Daniel R. Johnson, G. M. Haller, Michael Momayezi, Willy Langeveld	1995	42
7	Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours Journal of Immunological Methods ·Henrik N. Kløverpris, Anders Fomsgaard, Amanda J. Handley, Jim Ackland, Mark T. Sullivan, Philip Goulder	2010	39
8	A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2® in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet Gastroenterology ·Gregor J. Brown, A. James M. Daveson, Joanne K. Marjason, Rose A. Ffrench, Danielle Smith, Mark T. Sullivan, Jason A. Tye–Din, Robert P. Anderson	2011	31
9	Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques Vaccine ·Robert De Rose, Socheata Chea, C. Jane Dale, Jeanette C. Reece, Caroline S. Fernandez, Kim M Wilson, SCOTT A. THOMSON, Ian A. Ramshaw	2004	29
10	The Gravity Probe-B star-tracking telescope Advances in Space Research ·D.-H. Gwo, Sihong Wang, K. Bower, Donald E. Davidson, Paul Ehrensberger, Lynn W. Huff, Mark T. Sullivan, Kenneth J. Triebes	2003	28
11	Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever Drug Delivery and Translational Research ·Rosemary Wyber, Ben J. Boyd, Samantha Colquhoun, Bart J. Currie, Mark Emmanuel Engel, Joseph H. Kado, Ganesan Karthikeyan, Mark T. Sullivan	2016	27
12	Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis Journal of Hepatology ·Marion G. Peters, H.W. Hann, Paul B. Martin, Elizabeth Jenny Heathcote, Peter Buggisch, Alison Moorat, Mark T. Sullivan, Kristin Kleber	2002	25
13	Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years PLoS neglected tropical diseases ·Piero Olliaro, Annette C. Kuesel, Christine M Halleux, Mark T. Sullivan, John C. Reeder	2018	22
14	The Lunar Reconnaissance Orbiter Diviner Lunar Radiometer Experiment David A. Paige, M. C. Foote, Benjamin Greenhagen, John T. Schofield, S. B. Calcutt, Ashwin R. Vasavada, Daniel J. Preston, F. W. Taylor	2009	17
15	Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV Journal of Hepatology ·Yves Benhamou, M. Bochet, Roland Tubiana, Vincent Thibault, L. Suflisseau, Mark T. Sullivan, Jim Rooney, Carol L. Brosgart	2002	16
16	Development of the Gravity Probe B flight mission Advances in Space Research ·John P. Turneaure, C. W. F. Everitt, B. W. Parkinson, Doron Bardas, Saps Buchman, Daniel B. DeBra, H. Dougherty, Dale K. Gill	2003	16
17	Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection PLoS neglected tropical diseases ·Beesan Tan, Nicholas Obuobisa Opoku, Simon Kwaku Attah, Kwablah Awadzi, Annette C. Kuesel, Janis K. Lazdins-Helds, Craig R. Rayner, Victoria Ryg-Cornejo	2022	13
18	Evaluation of the Cardiac Safety of Long‐Acting Endectocide Moxidectin in a Randomized Concentration‐ QT Study Clinical and Translational Science ·Sally A. Kinrade, Jay W. Mason, Carlos R. Sanabria, Craig R. Rayner, Julie M. Bullock, Stephanie H. Stanworth, Mark T. Sullivan	2018	13
19	Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines: Implications for Future Trials Human Vaccines ·Robert De Rose, Mark T. Sullivan, C. Jane Dale, Anthony D. Kelleher, Sean Emery, David A. Cooper, Ian A. Ramshaw, David B. Boyle	2006	12
20	Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients Journal of Hepatology ·Yves Benhamou, M. Bochet, Vincent Thibault, Vincent Cálvez, M.‐H. Fievet, Mark T. Sullivan, Carol L. Brosgart, Hamid Namini	2002	12

About Mark T. Sullivan

Mark T. Sullivan is a scholar working on Virology, Infectious Diseases, Epidemiology, Aerospace Engineering and Astronomy and Astrophysics, having authored 54 papers that have together received 1.9k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (8 papers), HIV Research and Treatment (6 papers), Planetary Science and Exploration (6 papers), HIV/AIDS drug development and treatment (6 papers), Particle Accelerators and Free-Electron Lasers (5 papers), Space Science and Extraterrestrial Life (5 papers), Spacecraft and Cryogenic Technologies (4 papers) and Astro and Planetary Science (4 papers). The work is most often cited by research in Hepatology (479 citations), Epidemiology (808 citations), Astronomy and Astrophysics (378 citations), Infectious Diseases (216 citations) and Virology (55 citations). Mark T. Sullivan has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Carol L. Brosgart, Ramin Ebrahimi, Kristin Kleber, Paul B. Martin, Marion G. Peters, Peter Buggisch, Shengfeng Xiong, CHRISTIAN G. TREPO, E. Jenny Heathcote and Rainbow Rubin. Their work appears in journals such as Journal of Hepatology, Gastroenterology, PLoS neglected tropical diseases, American Journal of Health-System Pharmacy and Advances in Space Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark T. Sullivan

Impact in

Papers in i

In The Last Decade

Mark T. Sullivan

Peers

Countries citing papers authored by Mark T. Sullivan

Fields of papers citing papers by Mark T. Sullivan

All Works

About Mark T. Sullivan

Explore authors with similar magnitude of impact

Papers in